MedTrace Logo

Evaluating Pharmacogenomic Variants for Cardiology Therapeutics

NCT04702113 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2023-09-29

No results posted yet for this study

Summary

Cipherome's Lighthouse is a clinical decision support tool that incorporates a patient's pharmacogenetic information to determine therapeutic strategy, including determining appropriate dosage or assessing the likelihood of toxicity of a therapeutic regimen.

Conditions

Interventions

DIAGNOSTIC_TEST

Cipherome Lighthouse Pilot

Preemptive pharmacogenomic testing

Sponsors & Collaborators

  • DHR Health Institute for Research and Development

    collaborator OTHER

  • Cipherome, Inc.

    lead INDUSTRY

Principal Investigators

  • Herschl Silberman, MD · DHR Health

  • Humberto Mochizu Kitamayo, MD · DHR Health

  • Yetunde O Kare Opaneye, MD · DHR Health

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-03
Primary Completion
2023-07-26
Completion
2023-07-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04702113 on ClinicalTrials.gov